Cyclops is a medtech startup building clinical and wearable diagnostic and rehabilitation products for neuro vestibular disorders using eye tracking technology.
Introducing the Team at Cyclops
Cyclops’ founding team comprises of Dr. Srinivas Dorasala, Niranjan Subbarao and Dr. Ravi Nayar.
|The Team at Cyclops
Dr. Srinivas Dorasala is an ENT Surgeon specialising in neuro vestibular disorders with over 15 years of clinical and surgical experience. Prior to co-founding Cyclops Medtech, he was heading the department of ENT at BGS Global Hospital, Bangalore. He is a KOL in the space and conducts workshops and delivers lectures around the world regularly. He has many publications to his credit. At Cyclops, he takes care of product innovation and development.
Niranjan Subbarao is an entrepreneur and a marketing professional. This is his second startup in the medical space. Prior to cofounding Cyclops, he had founded a medical content and conferencing startup. At Cyclops, he is responsible for sales and marketing, strategy and partnerships.
Dr. Ravi Nayar is an ENT and Head Neck Surgeon and a senior academician. He was earlier heading the department of ENT at St. John’s Medical College and Research Centre. He is a medtech innovator and has mentored many young medtech startups. At Cyclops, he is the chief scientific officer.
In addition to the founders, Cyclops’ core team comprises of Shekar Tippur, CTO and Ajith Rao, Software Architect. Shekar specializes in data sciences and cloud computing. Ajith specialises in computer vision and image processing.
“Our core strength lies in our holistic team composition. We have clinical expertise, domain knowledge, technology expertise as well as business expertise amongst our core team members,” said Niranjan Subbarao, Co-founder, Cyclops MedTech.
India, despite having a very large medical device market is largely import driven. Here, we import close to 75% of our medical equipment and technology. The team at Cyclops believes, despite having abundant clinical knowledge, tech resources and patient pool, it’s unacceptable to be an import driven market. Dr. Srinivas, being a neuro vestibular practitioner, had identified many gaps in the diagnostic ecosystem which could be plugged with world-class Indian made products. During brain storming sessions, the dynamic team at Cyclops discovered that pupil tracking holds a lot of potential in diagnosing neuro vestibular disorders. There are over a billion patients worldwide suffering from neuro vestibular disorders. So, they saw a large patient base and inherent capability to innovate and build products for this space.
Cyclops’ first product- BalanceEye
Cyclops’ first product BalanceEye is being used to diagnose root cause for vertigo, balance disorders and stroke with acute vertiginous syndrome. The solution involves eye tracking goggles, image processing engine, cloud backbone and machine learning based interpretation modules. Primary users of the product are Neurologists, ENT Specialists and Audiologists.
Vertigo and dizziness are symptoms. Root cause can be in the inner ear, middle ear, brain stem, brain clot or even a tumour. BalanceEye diagnoses the root cause and helps clinicians pursue optimal treatment path. All these conditions present accurately measurable manifestations in the eyes. If tracked and interpreted accurately, they provide excellent diagnostic insights. The solution involves eye tracking goggles which capture eye video and sends the same to desktop where the image processing engine extracts values and graphs and sends the same to cloud. The ML module on the cloud analyses data and sends back accurate interpretations.
Conventionally, vertigo and balance assessment involved expensive equipment with dedicated physical infrastructure. Through its patent pending technology, the Bengaluru-based medtech startup has completely eliminated the need for dedicated physical infrastructure.
Talking more about BalanceEye, Dr. Srinivas Dorasala, Co-founder, Cyclops MedTech said, “BalanceEye can be used anywhere including clinical OPDs. For complete balance assessment, clinicians perform 3 major tests- Videonystagmography, Video Head Impulse test and Subjective Visual Vertical. Conventionally, all these 3 are available in different devices. With BalanceEye, clinicians can perform all these 3 tests through a single device.”
At Cyclops, the team of experienced professionals believes that their core proposition is:
- World class affordable solution
- Ease of use
- Support in interpretation
The core focus of founding team members was on getting the product out in the market. They wanted to launch a patient ready device with a very strong core offering. Once they were successful in that, they started releasing various modules around the core. For them, the next objective was to exploit their first mover advantage to the full extent and quickly consolidate their position in the market. Today, they are glad to note that in India, they have more installations in the market than combined installations of 5 major global competitors over the last few years. With its unique offering, Cyclops has achieved a great deal of traction in the last one year.
“We owe this to our strong and dedicated team, our early customers who were very encouraging and startup ecosystem partners,” added Niranjan Subbarao.
The team believes that it’s been a very adventures and adrenalin filled journey. They have been fortunate to find the right resources at the right time. Market response has been overwhelming and investor traction has been pretty good.
When asked about what keeps them going, Dr. Ravi Nayar, Co-founder, Cyclops MedTech said, “The billion patients with neuro vestibular disorders and a firm belief that we can make a difference to their lives through early diagnosis, cheaper diagnosis and accurate results.”
The team members are looking at Cyclops as a multi-product company with a strong focus on neuro vestibular disorders.
They have set themselves a very lofty target of 100 installations in the first year and they are happy to note that they’ve got very close to the target. In the coming year, they are launching 2 more products and are looking at further augmenting their market leadership in India and making rapid inroads into a few other markets in Asia where they have had initial successes.
We wish the team all the best for the future!